Clinical Trials Logo

Urothelial Bladder Carcinoma clinical trials

View clinical trials related to Urothelial Bladder Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06133517 Not yet recruiting - Clinical trials for Urothelial Bladder Carcinoma

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The main objective of this trial is to evaluate the efficacy of the combo Sacituzumab govitecan (SG) + Zimberelimab (AB 122) (ZIM) + Domvanalimab (AB 154) (DOM), measured as pathologic complete response (pCR) rates, in the perioperative setting in patients with Muscle Invasive Bladder Cancer (MIBC) who are either unfit for platinum-based chemotherapy or unwilling to receive that therapy.